Company
Ability Pharmaceuticals
- Biotech
- Space
- Founded:
- 2009
- Location:
- Barcelona, Spain
Description
Ability Pharmaceuticals develops oral targeted anticancer compounds that induce selective autophagy-mediated cytotoxicity in cancer cells; its candidate ABTL0812 activates PPARα and PPARγ, applying this approach in pancreatic, endometrial, and squamous non-small cell lung cancer.
Ability Pharmaceuticals is located in the Barcelona ecosystem.
Related
- Asgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
Prevision MedicinePrevision Medicine tests living cancer and healthy cells from a patient biopsy against 100+ drugs and combinations using a patented ex vivo…
Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
XENOTHERAXENOTHERA develops glyco humanized antibody technology for immunological treatments, lists pipeline products and clinical trials for…
Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
BiograilBiograil develops proprietary BIONDD® technology for oral delivery of biologics, using it in preclinical pharmaceutical work to turn…